Kenvue loses bid for rehearing after Tylenol autism lawsuits revived
Reuters
A federal appeals court denied Kenvue's request for a rehearing in the Tylenol autism lawsuits, allowing the cases to proceed after they were revived by a lower court. The decision means that claims linking the painkiller to autism spectrum disorder will continue to be considered in court. The ruling is a setback for the company as it faces potential liability from the ongoing litigation.
All articles from 19 October 2026. Summaries are AI-generated and may contain errors; the linked article is the authority.